Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.04 AUD
Change Today +0.003 / 8.11%
Volume 53.0K
As of 8:47 PM 10/1/15 All times are local (Market data is delayed by at least 15 minutes).

living cell technologies ltd (LCT) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/14 - A$0.08
52 Week Low
08/26/15 - A$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

living cell technologies ltd (LCT) Related Businessweek News

No Related Businessweek News Found

living cell technologies ltd (LCT) Details

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore function worldwide. The company’s therapeutic candidates include DIABECELL, which is in late-stage clinical trials for the treatment of type 1 diabetes; and NTCELL, which is in Phase I/IIa clinical trials for the treatment of Parkinson’s disease. It has a collaboration agreement with the Centre for Brain Research to identify neurodegenerative disease targets for clinical studies of NTCELL product. The company was founded in 1987 and is based in Auckland, New Zealand.

Founded in 1987

living cell technologies ltd (LCT) Top Compensated Officers

Chief Executive
Total Annual Compensation: A$317.0K
Co-Founder and Non-Executive Director
Total Annual Compensation: A$128.0K
Head of Finance & Administration
Total Annual Compensation: A$192.9K
Compensation as of Fiscal Year 2015.

living cell technologies ltd (LCT) Key Developments

Living Cell Technologies Limited Reports Earnings Results for the Year Ended June 30, 2015

Living Cell Technologies Limited reported earnings results for the year ended June 30, 2015. The company net loss for the financial year to 30 June 2015 was $7,043,402 compared to a loss of $6,778,896 in the prior year. The increased loss was due to the increased clinical trial activity and the absence of recovery of clinical trial expenses fee from Otsuka Pharmaceutical Factory Inc. as a result of termination of the co-development agreement in May 2014.

Living Cell Technologies Limited - Special Call

To discuss results from a Phase I/IIa clinical study of NTCELL®, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease

Living Cell Technologies Limited Announces Results from Phase I/IIa Clinical Study of NTCELL

Living Cell Technologies Limited announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. NTCELL implantation also improved clinical features of Parkinson’s disease in the four patients studied, as measured by validated neurological rating scales and questionnaires, with the improvement sustained at 26 weeks post-implant. The primary endpoint of the study was the safety of NTCELL implantation, which was assessed by the occurrence of adverse events and serious adverse events, as well as clinical and laboratory evidence of porcine endogenous retrovirus (PERV) in study participants and their partners. The secondary endpoint was efficacy, which was measured by validated neurological rating scales and questionnaires, including the Unified Parkinson’s Disease Rating Scale (UPDRS), the Unified Dyskinesia Rating Scale (UDysRS) and the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39) score. These scales assessed improvements in patients’ movement abnormalities, other physical symptoms, well-being and ability to perform everyday tasks. PET scans were conducted to measure the effects of NTCELL on dopamine brain metabolism. The results at week 26 following implantation were compared with those at baseline. In the study, NTCELL was well tolerated. There were no adverse events or serious adverse events related to NTCELL in any of the four patients. Eight adverse events occurred, all of which were considered to be related to the implant procedure and none to NTCELL. There was no clinical or laboratory evidence of PERV transmission in patients or their partners. MRIs showed no evidence of inflammation. All four patients experienced sustained improvement in clinical features as seen in UPDRS, UDysRs and PDQ-39 scores at week 26 post-implant. The first patient treated continued to show improvement in neurological scores at 74 weeks post- implantation. In this study, PET scan results did not show any consistent changes in the uptake of fluorodopa and tetrabenazine in the four patients, suggesting that the mechanism of NTCELL is not likely due to a direct change in dopaminergic neurons.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCT:AU A$0.04 AUD +0.003

LCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LCT.
View Industry Companies

Industry Analysis


Industry Average

Valuation LCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.6x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIVING CELL TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at